Tyrosine kinase 3D structures
From Proteopedia
(Difference between revisions)
Line 8: | Line 8: | ||
*'''Fyn tyrosine kinase''' (Domains: SH3 80-141; SH2 142-247; kinase 260-537) | *'''Fyn tyrosine kinase''' (Domains: SH3 80-141; SH2 142-247; kinase 260-537) | ||
- | **[[1shf]], [[3ua6]] – hTK Fyn SH3 domain – human<br /> | + | **[[1shf]], [[3ua6]], [[7a2j]], [[7a2k]] – hTK Fyn SH3 domain – human<br /> |
- | **[[3h0f]], [[3h0h]], [[3h0i]], [[3cqt]], [[6ipz]], [[6ipy]] - hTK Fyn SH3 domain (mutant)<br /> | + | **[[3h0f]], [[3h0h]], [[3h0i]], [[3cqt]], [[6ipz]], [[6ipy]], [[7a2l]], [[7a2m]], [[7a2n]], [[7a2o]], [[7a2p]], [[7a2q]], [[7a2r]],[[7a2s]], [[7a2t]], [[7a2u]], [[7a2v]] - hTK Fyn SH3 domain (mutant)<br /> |
- | **[[1zbj | + | **[[1zbj]] - hTK Fyn SH3 domain – NMR<br /> |
**[[1g83]] - hTK Fyn SH2+SH3 domains (mutant)<br /> | **[[1g83]] - hTK Fyn SH2+SH3 domains (mutant)<br /> | ||
- | **[[4u17]] – hTK Fyn SH2 domain<br /> | ||
- | **[[2mrj]], [[2mqi]] – hTK Fyn SH2 domain - NMR<br /> | ||
**[[6edf]] - hTK Fyn residues 1-77<br /> | **[[6edf]] - hTK Fyn residues 1-77<br /> | ||
**[[3uf4]] – mTK Fyn SH3-SH2 domain – mouse<br /> | **[[3uf4]] – mTK Fyn SH3-SH2 domain – mouse<br /> | ||
**[[3uf4]] - mTK Fyn SH2+SH3 domains<br /> | **[[3uf4]] - mTK Fyn SH2+SH3 domains<br /> | ||
- | **[[2l2p]], [[2lp5]] - cTK Fyn SH3 domain (mutant) - chicken - NMR<br /> | + | **[[2l2p]], [[2lp5]] - cTK Fyn SH3 domain (mutant)- chicken - NMR<br /> |
*Fyn complex | *Fyn complex | ||
Line 23: | Line 21: | ||
**[[1fyn]], [[4znx]] - hTK Fyn SH3 domain + peptide<br /> | **[[1fyn]], [[4znx]] - hTK Fyn SH3 domain + peptide<br /> | ||
**[[1nyf]], [[1nyg]], [[1a0n]], [[1azg]] - hTK Fyn SH3 domain + peptide – NMR<br /> | **[[1nyf]], [[1nyg]], [[1a0n]], [[1azg]] - hTK Fyn SH3 domain + peptide – NMR<br /> | ||
- | **[[5zau]] - hTK Fyn SH3 domain + monobody binder – NMR<br /> | ||
**[[1efn]], [[1avz]] - hTK Fyn SH3 domain + HIV Nef protein<br /> | **[[1efn]], [[1avz]] - hTK Fyn SH3 domain + HIV Nef protein<br /> | ||
**[[4d8d]], [[7d7s]] - hTK Fyn SH3 domain (mutant) + HIV Nef protein<br /> | **[[4d8d]], [[7d7s]] - hTK Fyn SH3 domain (mutant) + HIV Nef protein<br /> | ||
**[[1m27]] - hTK Fyn SH3 domain + SH2 domain protein 1A + SLAM peptide<br /> | **[[1m27]] - hTK Fyn SH3 domain + SH2 domain protein 1A + SLAM peptide<br /> | ||
- | **[[4d8d | + | **[[4d8d]] - hTK Fyn SH3 domain (mutant) + HIV Nef protein<br /> |
**[[3ua7]] – hTK Fyn SH3 domain + hepatitis virus peptide<br /> | **[[3ua7]] – hTK Fyn SH3 domain + hepatitis virus peptide<br /> | ||
**[[4eik]] - hTK Fyn SH3 domain + VSL12 peptide<br /> | **[[4eik]] - hTK Fyn SH3 domain + VSL12 peptide<br /> | ||
- | **[[ | + | **[[7a2w]], [[7a2x]], [[7a2y]], [[7a2z]] - hTK Fyn SH3 domain (mutant) + VSL12 peptide<br /> |
- | **[[1aot]], [[1aou | + | **[[1aot]], [[1aou]] - hTK Fyn SH2 domain + phosphopeptide - NMR<BR /> |
**[[2dq7]] – hTK kinase domain + staurosporine<br /> | **[[2dq7]] – hTK kinase domain + staurosporine<br /> | ||
Line 69: | Line 66: | ||
**[[6bl8]] - hTK kinase domain<br /> | **[[6bl8]] - hTK kinase domain<br /> | ||
**[[2g2h]] - hTK kinase domain (mutant)<br /> | **[[2g2h]] - hTK kinase domain (mutant)<br /> | ||
- | **[[ | + | **[[6xr6]], [[6xr7]], [[6xrg]] - hTK kinase domain (mutant) - NMR<br /> |
**[[2g1t]] - hTK kinase domain + peptide<br /> | **[[2g1t]] - hTK kinase domain + peptide<br /> | ||
**[[2g2i]], [[2g2f]] - hTK kinase domain (mutant) + peptide<br /> | **[[2g2i]], [[2g2f]] - hTK kinase domain (mutant) + peptide<br /> | ||
- | **[[3ue4]], [[3cs9]], [[2hzi]], [[2hz4]], [[2hz0]], [[2hyy]], [[2gqg]], [[4wa9]] - hTK kinase domain + cancer drug<br /> | + | **[[3ue4]], [[3cs9]], [[2hzi]], [[2hz4]], [[2hz0]], [[2hyy]], [[2gqg]], [[4wa9]], [[7n9g]] - hTK kinase domain + cancer drug<br /> |
**[[2f4j]], [[4twp]] - hTK kinase domain (mutant) + cancer drug<br /> | **[[2f4j]], [[4twp]] - hTK kinase domain (mutant) + cancer drug<br /> | ||
- | **[[3qrk]], [[3qri]], [[3qrj]], [[2v7a]], [[2e2b]], [[2hiw]], [[4zog]], [[5hu9]], [[4yc8]], [[3pyy]], [[6npv]], [[6npu]], [[6npe]] - hTK kinase domain + inhibitor<br /> | + | **[[3qrk]], [[3qri]], [[3qrj]], [[2v7a]], [[2e2b]], [[2hiw]], [[4zog]], [[5hu9]], [[4yc8]], [[3pyy]], [[6npv]], [[6npu]], [[6npe]], [[7cc2]], [[7dt2]], [[7w7x]], [[7w7y]] - hTK kinase domain + inhibitor<br /> |
**[[1opj]], [[1opk]] - mTK kinase domain <br /> | **[[1opj]], [[1opk]] - mTK kinase domain <br /> | ||
**[[1fpu]], [[1m52]], [[2qoh]], [[3kf4]], [[3kfa]] - mTK kinase domain + inhibitor<br /> | **[[1fpu]], [[1m52]], [[2qoh]], [[3kf4]], [[3kfa]] - mTK kinase domain + inhibitor<br /> | ||
Line 93: | Line 90: | ||
**[[1zzp]] - hTK abl F-actin binding domain – NMR <br /> | **[[1zzp]] - hTK abl F-actin binding domain – NMR <br /> | ||
- | |||
- | *Abl2 SH3 domain residues 110-166 | ||
- | |||
- | **[[5np3]] - hTK SH3 domain <BR /> | ||
- | **[[5np5]], [[5np2]] - hTK SH3 domain + phosphonotyrosine<BR /> | ||
*Abl2 SH2 domain residues 165-273 | *Abl2 SH2 domain residues 165-273 | ||
Line 114: | Line 106: | ||
**[[2kk1]] – hTK C terminal – NMR<BR /> | **[[2kk1]] – hTK C terminal – NMR<BR /> | ||
- | *'''Anaplastic lymphoma kinase (Alk)''' or | + | *'''Anaplastic lymphoma kinase (Alk)''' or Alk tyrosine kinae receptor; Domains – Gly-rich 678-986; TG+EGF=like 648-1030; kinase 1093-1411 |
**[[4tt7]], [[6cdt]] - hTK kinase domain<br /> | **[[4tt7]], [[6cdt]] - hTK kinase domain<br /> | ||
**[[3l9p]], [[3lcs]], [[3lct]], [[2yhv]], [[2yjr]], [[2yjs]], [[4fnw]], [[4fnx]], [[4anl]] - hTK kinase domain (mutant)<br /> | **[[3l9p]], [[3lcs]], [[3lct]], [[2yhv]], [[2yjr]], [[2yjs]], [[4fnw]], [[4fnx]], [[4anl]] - hTK kinase domain (mutant)<br /> | ||
- | **[[2xb7]], [[2xba]], [[3aox]], [[5imx]], [[5kz0]], [[4ccb]], [[4ccu]], [[4cli]], [[4cmo]], [[4cmt]], [[4cmu]], [[4cnh]], [[4ctb]], [[4ctc]], [[6mx8]], [[6edl]], [[6ebw]], [[6e0r]] - hTK kinase domain + inhibitor<br /> | + | **[[7lrz]], [[7mzw]], [[7mzy]] - hTK Gly-rich domain<br /> |
+ | **[[7nx4]] - hTK TG+EGF-like domain<br /> | ||
+ | **[[7nx3]] - hTK TG+EGF-like domain + antibody<br /> | ||
+ | **[[2xb7]], [[2xba]], [[3aox]], [[5imx]], [[5kz0]], [[4ccb]], [[4ccu]], [[4cli]], [[4cmo]], [[4cmt]], [[4cmu]], [[4cnh]], [[4ctb]], [[4ctc]], [[6mx8]], [[6edl]], [[6ebw]], [[6e0r]], [[7btt]], [[7jy4]], [[7jyr]], [[7jys]], [[7jyt]] - hTK kinase domain + inhibitor<br /> | ||
**[[4dce]], [[4fob]], [[4foc]], [[4fod]], [[4fny]], [[4fnz]], [[4joa]], [[4mkc]], [[4z55]], [[5iug]], [[5iuh]], [[5iui]], [[4cd0]], [[4clj]] - hTK kinase domain (mutant) + inhibitor<br /> | **[[4dce]], [[4fob]], [[4foc]], [[4fod]], [[4fny]], [[4fnz]], [[4joa]], [[4mkc]], [[4z55]], [[5iug]], [[5iuh]], [[5iui]], [[4cd0]], [[4clj]] - hTK kinase domain (mutant) + inhibitor<br /> | ||
- | **[[2xp2]], [[ | + | **[[2xp2]], [[5j7h]], [[5fto]], [[5ftq]] - hTK kinase domain + cancer drug<br /> |
**[[2yfx]], [[4anq]], [[4ans]], [[5aaa]], [[5aab]], [[5aac]], [[5a9u]], [[5aa8]], [[5aa9]] - hTK kinase domain (mutant) + cancer drug<br /> | **[[2yfx]], [[4anq]], [[4ans]], [[5aaa]], [[5aab]], [[5aac]], [[5a9u]], [[5aa8]], [[5aa9]] - hTK kinase domain (mutant) + cancer drug<br /> | ||
+ | **[[7n00], [[7nwz]]] - hTK kinase domain (mutant) + AUG-alpha<br /> | ||
+ | **[[7ls0]] - hTK kinase domain/AUG-alpha<br /> | ||
- | *'''Csk tyrosine | + | *'''Csk tyrosine kinase''' |
- | **[[3eac]] - hTK | + | **[[3eac]] - hTK SH2 domain<br /> |
- | **[[3eaz]] - hTK | + | **[[3eaz]] - hTK SH2 domain (mutant)<br /> |
- | **[[2rsy]] - hTK | + | **[[2rsy]] - hTK SH2 domain + CBP phosphopeptide - NMR<br /> |
- | **[[1csk]] - hTK | + | **[[1csk]] - hTK SH3 domain<br /> |
- | **[[1jeg]] - hTK | + | **[[1jeg]] - hTK SH3 domain + tyrosine phosphatase peptide - NMR<br /> |
- | **[[1byg]] - hTK | + | **[[1byg]] - hTK kinase domain + staurosporine<br /> |
- | **[[3d7t]], [[3d7u]] - hTK | + | **[[3d7t]], [[3d7u]] - hTK kinase domain (mutant) + C-Src<br /> |
- | **[[1k9a]] - TK | + | **[[1k9a]] - TK C terminal - rat<br /> |
*'''Jak tyrosine kinase''' see [[Janus kinase]] | *'''Jak tyrosine kinase''' see [[Janus kinase]] | ||
Line 140: | Line 137: | ||
**[[1blj]], [[1blk]] - mTK p55-blk SH2 domain – NMR<BR /> | **[[1blj]], [[1blk]] - mTK p55-blk SH2 domain – NMR<BR /> | ||
- | * '''Src tyrosine kinase''' or | + | * '''Src tyrosine kinase''' or proto-oncogene tyrosine protein kinase (Domains: SH3 85-140; SH2 140-251; kinase 253-535) |
*Src tyrosine kinase SH2 domain | *Src tyrosine kinase SH2 domain | ||
Line 154: | Line 151: | ||
**[[1f2f]] - cTK (mutant) <br /> | **[[1f2f]] - cTK (mutant) <br /> | ||
**[[1shd]] - cTK + TRKA receptor<br /> | **[[1shd]] - cTK + TRKA receptor<br /> | ||
+ | **[[1p13]] - cTK + peptide<br /> | ||
**[[1f1w]] - cTK (mutant) + peptide<br /> | **[[1f1w]] - cTK (mutant) + peptide<br /> | ||
- | **[[1p13]] - cTK + peptide<br /> | ||
**[[1spr]] - RsvTK + phosphate – Rous sarcoma virus<br /> | **[[1spr]] - RsvTK + phosphate – Rous sarcoma virus<br /> | ||
**[[2jyq]] – RsvTK – NMR<br /> | **[[2jyq]] – RsvTK – NMR<br /> | ||
Line 165: | Line 162: | ||
**[[6c4s]] – hTK + choline kinase peptide<br /> | **[[6c4s]] – hTK + choline kinase peptide<br /> | ||
- | **[[1jeg]] – mTK + protein-tyrosine phosphatase peptide <br /> | + | **[[1jeg]] – mTK + protein-tyrosine phosphatase peptide<br /> |
**[[1srl]], [[1srm]] - cTK – NMR<br /> | **[[1srl]], [[1srm]] - cTK – NMR<br /> | ||
**[[3fj5]], [[4jz3]], [[4jz4]], [[6xvo]], [[6xvn]] - cTK<br /> | **[[3fj5]], [[4jz3]], [[4jz4]], [[6xvo]], [[6xvn]] - cTK<br /> | ||
- | **[[4le9]], [[4oml]], [[4omm]], [[4omn]], [[4omo]], [[4omp]], [[4omq]], [[5i11]], [[4rtu]], [[4rtx]], [[ | + | **[[4le9]], [[4oml]], [[4omm]], [[4omn]], [[4omo]], [[4omp]], [[4omq]], [[5i11]], [[4rtu]], [[4rtx]], [[7a30]], [[7a31]], [[7a32]], [[7a33]], [[7a34]], [[7a35]], [[7a36]], [[7a37]], [[7a38]], [[7a39]], [[7a3a]], [[7a3b]], [[7a3c]], [[7a3d]], [[7a3e]], [[7ner]], [[7nes]], [[7net]] - cTK (mutant) <br /> |
**[[6xx3]], [[6xx2]], [[6xx5]], [[6xx4]], [[6xx5]], [[6xx2]] - cTK (mutant) + ion<br /> | **[[6xx3]], [[6xx2]], [[6xx5]], [[6xx4]], [[6xx5]], [[6xx2]] - cTK (mutant) + ion<br /> | ||
**[[4hxj]], [[1prl]], [[4qt7]], [[4rty]], [[4rtz]] - cTK + peptide<br /> | **[[4hxj]], [[1prl]], [[4qt7]], [[4rty]], [[4rtz]] - cTK + peptide<br /> | ||
Line 179: | Line 176: | ||
**[[1yo6]] - hTK <br /> | **[[1yo6]] - hTK <br /> | ||
**[[1yoj]] - hTK (mutant) <br /> | **[[1yoj]] - hTK (mutant) <br /> | ||
- | **[[2bdf]], [[2bdj]], [[6e6e]], [[6ate]] – hTK + inhibitor<br /> | + | **[[2bdf]], [[2bdj]], [[6e6e]], [[6ate]], [[7ng7]] – hTK + inhibitor<br /> |
**[[1yol]], [[1yom]] – hTK (mutant) + inhibitor<br /> | **[[1yol]], [[1yom]] – hTK (mutant) + inhibitor<br /> | ||
**[[1byg]] – hTK + staurosporine<br /> | **[[1byg]] – hTK + staurosporine<br /> | ||
Line 185: | Line 182: | ||
**[[4mxx]], [[4mxy]], [[4mxz]] – hTK (mutant) + cancer drug<br /> | **[[4mxx]], [[4mxy]], [[4mxz]] – hTK (mutant) + cancer drug<br /> | ||
**[[3of0]], [[2qi8]] - cTK (mutant) <br /> | **[[3of0]], [[2qi8]] - cTK (mutant) <br /> | ||
+ | **[[3d7t]], [[3d7u]] – cTK + Csk<br /> | ||
+ | **[[3dqw]], [[3dqx]] - cTK (mutant) + ATP<br /> | ||
**[[3tz7]], [[3tz8]], [[3tz9]], [[4dgg]] – cTK (mutant) + pyrazolin derivative<br /> | **[[3tz7]], [[3tz8]], [[3tz9]], [[4dgg]] – cTK (mutant) + pyrazolin derivative<br /> | ||
- | **[[4fic]], [[3uqg]], [[3uqf]], [[3u51]], [[3u4w]], [[4agw]], [[3qlg]], [[3qlf]], [[3g6g]], [[3el8]], [[3f6x]], [[2hwo]], [[2hwp]], [[2oiq]], [[3en4]], [[3en5]], [[3en6]], [[3en7]], [[3el7]], [[5bmm]], [[5j5s]], [[4ybj]], [[4ybk]], [[5xp7]], [[ | + | **[[4fic]], [[3uqg]], [[3uqf]], [[3u51]], [[3u4w]], [[4agw]], [[3qlg]], [[3qlf]], [[3g6g]], [[3el8]], [[3f6x]], [[2hwo]], [[2hwp]], [[2oiq]], [[3en4]], [[3en5]], [[3en6]], [[3en7]], [[3el7]], [[5bmm]], [[5j5s]], [[4ybj]], [[4ybk]], [[5xp7]], [[7ah3]], [[7d57]], [[7d5o]] – cTK + inhibitor<br /> |
+ | **[[7wf5]] – cTK + cancer drug<br /> | ||
**[[4lgg]], [[4lgh]], [[3svv]], [[3oez]], [[3lok]], [[3g5d]], [[3f3w]], [[3f3v]], [[3geq]], [[3g6h]], [[3f3t]], [[3f3u]], [[2qlq]], [[2qq7]], [[4lgg]], [[4lgh]], [[4mcv]], [[4o2p]], [[5teh]], [[5t0p]], [[5sys]], [[5swh]], [[6hve]], [[6hvf]] – cTK (mutant) + inhibitor<br /> | **[[4lgg]], [[4lgh]], [[3svv]], [[3oez]], [[3lok]], [[3g5d]], [[3f3w]], [[3f3v]], [[3geq]], [[3g6h]], [[3f3t]], [[3f3u]], [[2qlq]], [[2qq7]], [[4lgg]], [[4lgh]], [[4mcv]], [[4o2p]], [[5teh]], [[5t0p]], [[5sys]], [[5swh]], [[6hve]], [[6hvf]] – cTK (mutant) + inhibitor<br /> | ||
- | **[[6l8l]] – cTK + cancer drug<br /> | ||
**[[4u5j]] – cTK (mutant) + cancer drug<br /> | **[[4u5j]] – cTK (mutant) + cancer drug<br /> | ||
- | **[[3d7t]], [[3d7u]] – cTK + Csk<br /> | ||
- | **[[3dqw]], [[3dqx]] - cTK (mutant) + ATP<br /> | ||
*Src tyrosine kinase C terminal domain | *Src tyrosine kinase C terminal domain | ||
Line 242: | Line 239: | ||
*'''Syk - spleen tyrosine kinase''' | *'''Syk - spleen tyrosine kinase''' | ||
- | **[[1xba]], [[4xg2]] – hSyk kinase domain | + | **[[1xba]], [[4xg2]] – hSyk kinase domain residues 337-635 |
*Syk complex | *Syk complex | ||
Line 248: | Line 245: | ||
**[[1xbb]] - hSyk kinase domain + Gleevec<br /> | **[[1xbb]] - hSyk kinase domain + Gleevec<br /> | ||
**[[1xbc]] - hSyk kinase domain + staurosporine<br /> | **[[1xbc]] - hSyk kinase domain + staurosporine<br /> | ||
- | **[[3emg]], [[3fqe]], [[3fqh]], [[3fqs]], [[3srv]], [[4dfl]], [[4dfn]], [[3vf8]], [[3vf9]], [[3tub]], [[3tuc]], [[3tud]], [[4f4p]], [[4fyn]], [[4fyo]], [[4fz6]], [[4fz7]], [[4gfg]], [[4i0r]], [[4i0s]], [[4i0t]], [[4puz]], [[4pv0]], [[4rx7]], [[4rx8]], [[4rx9]], [[5lma]], [[5lmb]], [[5ghv]], [[4wnm]], [[4xg3]], [[4xg4]], [[4xg6]], [[4xg7]], [[4xg8]], [[4xg9]], [[4rss]], [[4yjv]], [[5c26]], [[5c27]], [[4yjo]], [[4yjp]], [[4yjq]], [[4yjr]], [[4yjs]], [[4yjt]], [[4yju]], [[5tr6]], [[5tt7]], [[5tiu]], [[5t68]], [[5y5t]], [[5y5u]], [[4gfg]], [[6hm6]], [[6hm7]], [[6vov]], [[ | + | **[[3emg]], [[3fqe]], [[3fqh]], [[3fqs]], [[3srv]], [[4dfl]], [[4dfn]], [[3vf8]], [[3vf9]], [[3tub]], [[3tuc]], [[3tud]], [[4f4p]], [[4fyn]], [[4fyo]], [[4fz6]], [[4fz7]], [[4gfg]], [[4i0r]], [[4i0s]], [[4i0t]], [[4puz]], [[4pv0]], [[4rx7]], [[4rx8]], [[4rx9]], [[5lma]], [[5lmb]], [[5ghv]], [[4wnm]], [[4xg3]], [[4xg4]], [[4xg6]], [[4xg7]], [[4xg8]], [[4xg9]], [[4rss]], [[4yjv]], [[5c26]], [[5c27]], [[4yjo]], [[4yjp]], [[4yjq]], [[4yjr]], [[4yjs]], [[4yjt]], [[4yju]], [[5tr6]], [[5tt7]], [[5tiu]], [[5t68]], [[5y5t]], [[5y5u]], [[4gfg]], [[6hm6]], [[6hm7]], [[6vov]], [[6zc0]], [[6zcp]], [[6zcq]], [[6zcr]], [[6zcs]], [[6zcu]], [[6zcx]], [[6zcy]] - hSyk kinase domain + inhibitor<br /> |
**[[4px6]], [[5cxh]], [[5cxz]], [[5cy3]] - hSyk kinase domain (mutant) + inhibitor<br /> | **[[4px6]], [[5cxh]], [[5cxz]], [[5cy3]] - hSyk kinase domain (mutant) + inhibitor<br /> | ||
**[[1csy]], [[1csz]] - hSyk SH2 domain + phosphopeptide – NMR<BR /> | **[[1csy]], [[1csz]] - hSyk SH2 domain + phosphopeptide – NMR<BR /> | ||
**[[4fl1]], [[4fl2]] - hSyk kinase domain + ANP<br /> | **[[4fl1]], [[4fl2]] - hSyk kinase domain + ANP<br /> | ||
**[[4fl3]] - hSyk kinase domain (mutant) + ANP<br /> | **[[4fl3]] - hSyk kinase domain (mutant) + ANP<br /> | ||
- | **[[1a81]] – hSyk tandem SH2 domain + T-cell surface peptide <br /> | + | **[[7q63]], [[7sa7]] – hSyk tandem SH2 domain <br /> |
+ | **[[1a81]], [[7q5t]], [[7q5u]], [[7q5w]] – hSyk tandem SH2 domain + T-cell surface peptide <br /> | ||
- | *'''Itk/Tsk tyrosine kinase''' or | + | *'''Itk/Tsk tyrosine kinase''' or interleukin-2 tyrosine kinase; domains – SH2 236-344; SH3 160-236; kinase 357-620 |
**[[2etz]], [[2eu0]] – hTK Itk SH2 domain + phosphopeptide – NMR<BR /> | **[[2etz]], [[2eu0]] – hTK Itk SH2 domain + phosphopeptide – NMR<BR /> | ||
Line 284: | Line 282: | ||
**[[1u59]] - hTK Zap-70 kinase domain + staurosporine | **[[1u59]] - hTK Zap-70 kinase domain + staurosporine | ||
- | *'''Pyk2 tyrosine kinase or protein-tyrosine kinase 2-β (Domains: kinase 414-692; FAT 861-1009)''' | + | *'''Pyk2 tyrosine kinase or or protein-tyrosine kinase 2-β (Domains: kinase 414-692; FAT 861-1009)''' |
**[[3cc6]], [[3fzo]] - hTK Pyk2 kinase domain <br /> | **[[3cc6]], [[3fzo]] - hTK Pyk2 kinase domain <br /> | ||
Line 313: | Line 311: | ||
**[[6kc4]] - hTK Fer SH2 domain + phosphopeptide<BR /> | **[[6kc4]] - hTK Fer SH2 domain + phosphopeptide<BR /> | ||
- | *'''Ptk6 tyrosine kinase or breast tumor kinase Brk | + | *'''Ptk6 tyrosine kinase or breast tumor kinase Brk''' |
**[[1rja]] - hTK Ptk6 SH2 domain – NMR<br /> | **[[1rja]] - hTK Ptk6 SH2 domain – NMR<br /> | ||
Line 320: | Line 318: | ||
**[[5da3]], [[6cz3]], [[6cz4]] - hTK Ptk6 kinase domain + inhibitor<br /> | **[[5da3]], [[6cz3]], [[6cz4]] - hTK Ptk6 kinase domain + inhibitor<br /> | ||
**[[5h2u]] - hTK Ptk6 kinase domain (mutant) + cancer drug<br /> | **[[5h2u]] - hTK Ptk6 kinase domain (mutant) + cancer drug<br /> | ||
- | |||
- | *'''Ptk7 tyrosine kinase''' | ||
- | |||
- | **[[6vg3]] - hTK Ptk7 kinase domain<br /> | ||
*'''PtkA tyrosine kinase''' | *'''PtkA tyrosine kinase''' | ||
Line 372: | Line 366: | ||
**[[3la6]] - EcTK Wzc kinase domain <br /> | **[[3la6]] - EcTK Wzc kinase domain <br /> | ||
+ | **[[7ni2]], [[7nib]] - EcTK Wzc – Cryo EM <br /> | ||
+ | **[[7dhd]] - VvTK Wzc – Vibrio vulnificus <br /> | ||
+ | **[[7dhe]], [[7dhf]] - VvTK Wzc + inhibitor <br /> | ||
*'''Ros tyrosine kinase''' | *'''Ros tyrosine kinase''' | ||
Line 378: | Line 375: | ||
**[[4uxl]] - hTK Ros kinase domain + inhibitor<br /> | **[[4uxl]] - hTK Ros kinase domain + inhibitor<br /> | ||
- | *'''Tyk2 tyrosine kinase''' (Domains: SH2+FERM 23-540; pseudokinase 541-880; kinase 880-1170) | + | *'''Non-receptor Tyk2 tyrosine kinase''' (Domains: SH2+FERM 23-540; pseudokinase 541-880; kinase 880-1170) |
- | **[[5f20]], [[5f1z]], [[6ova | + | **[[5f20]], [[5f1z]], [[6ova]] - hTK Tyk2 kinase domain + inhibitor<br /> |
**[[3lxn]], [[3lxp]], [[3nyx]], [[3nz0]], [[4e1z]], [[4e20]], [[4gfo]], [[4gih]], [[4gii]], [[4gj2]], [[4gj3]], [[4py1]], [[5wal]], [[5wev]], [[6dbk]], [[6dbm]] - hTK Tyk2 kinase domain (mutant) + inhibitor<br /> | **[[3lxn]], [[3lxp]], [[3nyx]], [[3nz0]], [[4e1z]], [[4e20]], [[4gfo]], [[4gih]], [[4gii]], [[4gj2]], [[4gj3]], [[4py1]], [[5wal]], [[5wev]], [[6dbk]], [[6dbm]] - hTK Tyk2 kinase domain (mutant) + inhibitor<br /> | ||
- | **[[6aam]], [[6x8g]], [[6x8f]] - hTK Tyk2 kinase domain (mutant) + | + | **[[6aam]], [[6x8g]], [[6x8f]] - hTK Tyk2 kinase domain (mutant) + drug<br /> |
**[[4gvj]] - hTK Tyk2 kinase domain (mutant) + ADP<br /> | **[[4gvj]] - hTK Tyk2 kinase domain (mutant) + ADP<br /> | ||
**[[4oli]] - hTK Tyk2 pseudokinase + kinase domains <br /> | **[[4oli]] - hTK Tyk2 pseudokinase + kinase domains <br /> | ||
**[[3zon]], [[5c01]], [[5c03]] - hTK Tyk2 pseudokinase domain <br /> | **[[3zon]], [[5c01]], [[5c03]] - hTK Tyk2 pseudokinase domain <br /> | ||
- | **[[4wov]], [[5tkd]], [[6nzr]], [[6nzq]], [[6nzp]], [[6nzh]], [[6nzf]], [[6nze]], [[6nsl]] - hTK Tyk2 pseudokinase domain + inhibitor<br /> | + | **[[4wov]], [[5tkd]], [[6nzr]], [[6nzq]], [[6nzp]], [[6nzh]], [[6nzf]], [[6nze]], [[6nsl]], [[7ax4]], [[7k7o]], [[7k7q]] - hTK Tyk2 pseudokinase domain + inhibitor<br /> |
**[[4po6]] - hTK Tyk2 SH2+FERM domains + IFNAR1 peptide<br /> | **[[4po6]] - hTK Tyk2 SH2+FERM domains + IFNAR1 peptide<br /> | ||
*'''Hck tyrosine kinase''' Domains: SH3 81-137; SH2 119-224; SH1 or kinase+C-terminal 225-525; | *'''Hck tyrosine kinase''' Domains: SH3 81-137; SH2 119-224; SH1 or kinase+C-terminal 225-525; | ||
- | **[[3hck]] - hTK | + | **[[3hck]] - hTK SH2 domain - NMR<BR /> |
- | **[[1bu1]] - hTK | + | **[[1bu1]] - hTK SH3 domain <BR /> |
- | **[[4hck]], [[5hck]] - hTK | + | **[[4hck]], [[5hck]] - hTK SH3 domain - NMR<BR /> |
- | **[[2oj2]], [[2oi3]] - hTK | + | **[[2oj2]], [[2oi3]] - hTK SH3 domain + peptide - NMR<BR /> |
- | **[[3rbb]], [[3rea]], [[3reb]] - hTK | + | **[[3rbb]], [[3rea]], [[3reb]] - hTK SH3 domain (mutant) + HIV NEF<BR /> |
- | **[[5nuh]] - hTK | + | **[[5nuh]] - hTK SH3 domain + SIV NEF<BR /> |
- | **[[4orz]] - hTK | + | **[[4orz]] - hTK SH3 domain (mutant) + HIV NEF + single domain antibody<br /> |
- | **[[3nhn]] - hTK | + | **[[3nhn]] - hTK SH3-SH2-linker domain <BR /> |
**[[4u5w]] - hTK Hck SH3-SH2 domains + NEF <br /> | **[[4u5w]] - hTK Hck SH3-SH2 domains + NEF <br /> | ||
- | **[[2c0i]], [[2c0o]], [[2c0t]] - hTK | + | **[[2c0i]], [[2c0o]], [[2c0t]] - hTK SH3-SH2-SH1 domain + inhibitor<BR /> |
- | **[[5h0b]], [[5h0e]], [[5h0g]], [[5h0h]] - hTK | + | **[[5h0b]], [[5h0e]], [[5h0g]], [[5h0h]] - hTK SH3-SH2-SH1 domain (mutant) + inhibitor<BR /> |
- | **[[2hk5]], [[5zj6]] - hTK | + | **[[2hk5]], [[5zj6]] - hTK kinase domain + inhibitor<BR /> |
- | **[[1qcf]], [[3vrz]], [[3vs0]], [[3vs3]], [[3vs4]], [[3vs5]], [[3vs6]], [[3vs7]] - hTK | + | **[[1qcf]], [[3vrz]], [[3vs0]], [[3vs3]], [[3vs4]], [[3vs5]], [[3vs6]], [[3vs7]] - hTK SH3-SH2-kinase-C-terminal domain + inhibitor<BR /> |
- | **[[3vry]], [[3vs1]], [[3vs2]] - hTK | + | **[[3vry]], [[3vs1]], [[3vs2]] - hTK SH3-SH2-kinase-C-terminal domain (mutant) + inhibitor<BR /> |
- | **[[1ad5]] - hTK | + | **[[1ad5]] - hTK SH3-SH2-kinase-C-terminal domain + AMPPNP<BR /> |
- | **[[2hck]] - hTK | + | **[[2hck]] - hTK SH3-SH2-kinase-C-terminal domain + quercetin<BR /> |
- | **[[4lud]], [[4lue]] - hTK | + | **[[4lud]], [[4lue]] - hTK SH2+SH3+kinase+C-terrminal domain (mutant) + fluorescent compound<br /> |
- | *'''Ack1 tyrosine kinase''' or | + | *'''Ack1 tyrosine kinase''' or activated cdc42 kinase 1 |
**[[1u46]], [[4hzr]] - hTK Ack1 kinase domain <br /> | **[[1u46]], [[4hzr]] - hTK Ack1 kinase domain <br /> | ||
**[[4hzs]] - hTK Ack1 kinase+SH3 domains <br /> | **[[4hzs]] - hTK Ack1 kinase+SH3 domains <br /> | ||
- | **[[1u54]] - hTK Ack1 kinase domain + AMPPCP <br /> | ||
**[[1u4d]], [[3eqp]], [[3eqr]], [[4ewh]], [[4id7]], [[5zxb]] - hTK Ack1 kinase domain + inhibitor<br /> | **[[1u4d]], [[3eqp]], [[3eqr]], [[4ewh]], [[4id7]], [[5zxb]] - hTK Ack1 kinase domain + inhibitor<br /> | ||
*'''RECEPTOR TYROSINE KINASES - RTK''' | *'''RECEPTOR TYROSINE KINASES - RTK''' | ||
- | *'''Bruton’s tyrosine kinase | + | *'''Bruton’s tyrosine kinase''' (Domains: PH 1-170; SH3 216-273; SH2 273-378; kinase 378-659) |
**[[2z0p]] - hTK Btk PH domain<br /> | **[[2z0p]] - hTK Btk PH domain<br /> | ||
- | **[[1btk | + | **[[1btk]] – hTK Btk PH domain (mutant) <br /> |
**[[3p08]], [[1k2p]] - hTK Btk kinase domain<br /> | **[[3p08]], [[1k2p]] - hTK Btk kinase domain<br /> | ||
**[[1aww]], [[1awx]], [[1qly]] - hTK Btk SH3 domain – NMR<BR /> | **[[1aww]], [[1awx]], [[1qly]] - hTK Btk SH3 domain – NMR<BR /> | ||
Line 432: | Line 428: | ||
**[[1b55]] - hTK Btk PH domain + inositol-tetrakisphosphate<br /> | **[[1b55]] - hTK Btk PH domain + inositol-tetrakisphosphate<br /> | ||
- | **[[6tse]], [[6tvn]] - hTK Btk PH domain (mutant) + indoline derivative<br /> | ||
**[[1bwn]] - hTK Btk PH domain (mutant) + inositol-tetrakisphosphate<br /> | **[[1bwn]] - hTK Btk PH domain (mutant) + inositol-tetrakisphosphate<br /> | ||
- | **[[ | + | **[[6yyf]], [[6yyg]], [[6yyk]] - hTK Btk PH domain (mutant) + inhibitor<br /> |
- | **[[3gen]], [[3ocs]], [[3pix]], [[3piy]], [[3piz]], [[3pj1]], [[3pj2]], [[3pj3]], [[4nwm]], [[4yhf]], [[5jrs]], [[5fbo]], [[5fbn]], [[4rx5]], [[5bpy]], [[5bq0]], [[5vgo]], [[5u9d]], [[5t18]], [[5p9m]], [[5p9l]], [[5p9m]], [[5p9l]], [[5p9f]], [[5p9g]], [[5p9h]], [[5p9i]], [[5p9j]], [[5p9k]], [[5vfi]], [[4z3v]], [[4zly]], [[4zlz]], [[5zz4]], [[6aua]], [[6aub]], [[5j87]], [[5xyz]], [[6bik]], [[6bke]], [[6bkh]], [[6bkw]], [[6bln]], [[6di0]], [[6di1]], [[6di3]], [[6di5]], [[6di9]], [[6e4f]], [[6e9p]], [[5kup]], [[6tfp]], [[6s90]], [[6o8i]], [[6nzm]], [[6nfi]], [[6nfh]], [[6n9p]], [[6w07]], [[6w06]], [[6vxq]], [[ | + | **[[3gen]], [[3ocs]], [[3pix]], [[3piy]], [[3piz]], [[3pj1]], [[3pj2]], [[3pj3]], [[4nwm]], [[4yhf]], [[5jrs]], [[5fbo]], [[5fbn]], [[4rx5]], [[5bpy]], [[5bq0]], [[5vgo]], [[5u9d]], [[5t18]], [[5p9m]], [[5p9l]], [[5p9m]], [[5p9l]], [[5p9f]], [[5p9g]], [[5p9h]], [[5p9i]], [[5p9j]], [[5p9k]], [[5vfi]], [[4z3v]], [[4zly]], [[4zlz]], [[5zz4]], [[6aua]], [[6aub]], [[5j87]], [[5xyz]], [[6bik]], [[6bke]], [[6bkh]], [[6bkw]], [[6bln]], [[6di0]], [[6di1]], [[6di3]], [[6di5]], [[6di9]], [[6e4f]], [[6e9p]], [[5kup]], [[6tfp]], [[6s90]], [[6o8i]], [[6nzm]], [[6nfi]], [[6nfh]], [[6n9p]], [[6w07]], [[6w06]], [[6vxq]], [[6x3n]], [[6x3o]], [[6x3p]], [[6xe4]], [[7kxl]], [[7kxm]], [[7kxn]], [[7kxo]], [[7kxp]], [[7kxq]], [[7lty]], [[7ltz]], [[7n4q]], [[7n4r]], [[7n4s]], [[7n5o]], [[7n5r]], [[7n5x]], [[7n5y]], [[7r60]], [[7r61]] - hTK Btk kinase domain + inhibitor<br /> |
**[[3k54]], [[3t9t]], [[4ot5]], [[4ot6]], [[4otq]], [[4otr]], [[4otf]], [[4rfy]], [[4rfz]], [[4rg0]], [[6ep9]], [[6hrt]], [[6hrp]] - hTK Btk kinase domain (mutant) + inhibitor<br /> | **[[3k54]], [[3t9t]], [[4ot5]], [[4ot6]], [[4otq]], [[4otr]], [[4otf]], [[4rfy]], [[4rfz]], [[4rg0]], [[6ep9]], [[6hrt]], [[6hrp]] - hTK Btk kinase domain (mutant) + inhibitor<br /> | ||
- | **[[ | + | **[[6w7o]], [[6w8i]] - hTK Btk kinase domain + cIAP + inhibitor<br /> |
+ | **[[5vgo]] - hTK Btk kinase domain + cancer drug<br /> | ||
**[[3oct]] - hTK Btk kinase domain (mutant) + cancer drug<br /> | **[[3oct]] - hTK Btk kinase domain (mutant) + cancer drug<br /> | ||
**[[6omu]] - hTK Btk kinase domain + MS drug<br /> | **[[6omu]] - hTK Btk kinase domain + MS drug<br /> | ||
Line 446: | Line 442: | ||
*'''c-FMS tyrosine kinase or macrophage colony-stimulating factor 1 receptor''' see [[Colony-stimulating factor receptor]] | *'''c-FMS tyrosine kinase or macrophage colony-stimulating factor 1 receptor''' see [[Colony-stimulating factor receptor]] | ||
- | + | *'''Kit tyrosine kinase''' or mast/stem cell growth factor receptor Kit; Domains – extracellular 1-519; kinase 547-693, 754-935 | |
- | + | ||
- | *'''Kit tyrosine kinase''' or | + | |
**[[2ec8]] - hTK Kit extracellular domain<br /> | **[[2ec8]] - hTK Kit extracellular domain<br /> | ||
+ | **[[3g0e]], [[3g0f]] - hTK Kit kinase domain (mutant) + cancer drug<br /> | ||
**[[2e9w]] - hTK Kit extracellular domain + stem cell factor<br /> | **[[2e9w]] - hTK Kit extracellular domain + stem cell factor<br /> | ||
**[[1t45]], [[4pgz]] - hTK Kit kinase domain<br /> | **[[1t45]], [[4pgz]] - hTK Kit kinase domain<br /> | ||
**[[1t46]], [[4u0i]], [[6mob]], [[6kla]] - hTK Kit kinase domain + cancer drug<br /> | **[[1t46]], [[4u0i]], [[6mob]], [[6kla]] - hTK Kit kinase domain + cancer drug<br /> | ||
- | **[[6gqj]], [[6gql]], [[6gqm]], [[6gqk | + | **[[6gqj]], [[6gql]], [[6gqm]], [[6gqk]] - hTK Kit kinase domain (mutant) + cancer drug<br /> |
- | **[[6itv]], [[6itt]], [[6xv9]], [[6xva]], [[6xvb]] - hTK Kit kinase domain + inhibitor<br /> | + | **[[6itv]], [[6itt]], [[6xv9]], [[6xva]], [[6xvb]], [[7khg]], [[7khj]], [[7khk]] - hTK Kit kinase domain + inhibitor<br /> |
**[[4hvs]], [[6hh1]] - hTK Kit kinase domain (mutant) + inhibitor<br /> | **[[4hvs]], [[6hh1]] - hTK Kit kinase domain (mutant) + inhibitor<br /> | ||
**[[2o26]] - hTK Kit residues 25-314 + Kit ligand<br /> | **[[2o26]] - hTK Kit residues 25-314 + Kit ligand<br /> | ||
Line 470: | Line 465: | ||
**[[3brb]] - hTK Mer kinase domain + ADP<br /> | **[[3brb]] - hTK Mer kinase domain + ADP<br /> | ||
**[[2p0c]] - hTK Mer kinase domain + ANP<br /> | **[[2p0c]] - hTK Mer kinase domain + ANP<br /> | ||
- | **[[3bpr]], [[3tcp]], [[4m3q]], [[4mh7]], [[4mha]], [[5u6c]], [[5tc0]], [[5k0k]], [[5k0x]], [[5td2]], [[6mep]], [[ | + | **[[3bpr]], [[3tcp]], [[4m3q]], [[4mh7]], [[4mha]], [[5u6c]], [[5tc0]], [[5k0k]], [[5k0x]], [[5td2]], [[6mep]], [[7m5z]] - hTK Mer kinase domain + inhibitor<br /> |
**[[7ab2]], [[7aax]], [[7aaz]] - hTK Mer kinase domain (mutant) + inhibitor<br /> | **[[7ab2]], [[7aax]], [[7aaz]] - hTK Mer kinase domain (mutant) + inhibitor<br /> | ||
**[[7ab1]] - hTK Mer kinase domain + anti-cancer drug<br /> | **[[7ab1]] - hTK Mer kinase domain + anti-cancer drug<br /> | ||
Line 487: | Line 482: | ||
*'''ErbB tyrosine kinase''' see [[Epidermal Growth Factor Receptor]] | *'''ErbB tyrosine kinase''' see [[Epidermal Growth Factor Receptor]] | ||
- | *'''MuSK | + | *'''MuSK tyrosine kinase''' |
**[[3hkl]] - rTK MuSK Fz-Crd domain <br /> | **[[3hkl]] - rTK MuSK Fz-Crd domain <br /> | ||
Line 496: | Line 491: | ||
**[[5ve6]] - hTK <br /> | **[[5ve6]] - hTK <br /> | ||
- | *'''Matk tyrosine kinase''' or | + | *'''Matk tyrosine kinase''' or megakaryocyte-associated tyrosine-protein kinase |
**[[3us4]] - hTK Matk SH2 domain <br /> | **[[3us4]] - hTK Matk SH2 domain <br /> | ||
+ | **[[1x6g]] - hTK Matk SH3 domain - NMR<br /> | ||
- | + | *'''Flt3 tyrosine kinase''' | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | *'''Flt3 tyrosine kinase''' | + | |
**[[1rjb]] - hTK Flt3 kinase domain <br /> | **[[1rjb]] - hTK Flt3 kinase domain <br /> | ||
**[[4rt7]], [[6il3]], [[5x02]] - hTK Flt3 kinase domain + inhibitor<br /> | **[[4rt7]], [[6il3]], [[5x02]] - hTK Flt3 kinase domain + inhibitor<br /> | ||
- | **[[ | + | **[[6jqr]] - hTK Flt3 kinase domain + leukemia drug<br / |
- | **[[ | + | **[[4xuf]] - hTK Flt3 kinase domain (mutant) + leukemia drug<br /> |
+ | **[[3qs7]], [[3qs9]] - hTK Flt3 kinase domain + SL cytokine<br / | ||
*'''Tie2 tyrosine kinase''' | *'''Tie2 tyrosine kinase''' | ||
Line 520: | Line 508: | ||
**[[1fvr]] - hTK Tie2 kinase domain <br /> | **[[1fvr]] - hTK Tie2 kinase domain <br /> | ||
- | *'''Ret tyrosine kinase''' or | + | *'''Ret tyrosine kinase''' or proto-oncogene tyrosine protein kinase receptor Ret |
**[[6nja]] - hTK Ret kinase domain<br /> | **[[6nja]] - hTK Ret kinase domain<br /> | ||
**[[6fek]] - hTK Ret kinase domain (mutant)<br /> | **[[6fek]] - hTK Ret kinase domain (mutant)<br /> | ||
- | + | **[[5amn]], [[6vhg]], [[7run]] - hTK Ret kinase domain + inhibitor<br /> | |
- | + | ||
- | + | ||
- | **[[5amn]], [[6vhg]], [[ | + | |
**[[6i83]], [[6i82]] - hTK Ret kinase domain (mutant) + inhibitor<br /> | **[[6i83]], [[6i82]] - hTK Ret kinase domain (mutant) + inhibitor<br /> | ||
- | **[[6nec]], [[6ne7]], [[7ju5]] | + | **[[6nec]], [[6ne7]], [[7ju5]] |
- | **[[4ux8]] - hTK Ret extracellular domain + GFR | + | - hTK Ret kinase domain + cancer drug<br /> |
- | + | **[[4ux8]] - hTK Ret extracellular domain + GFR alpha 1<br /> | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
+ | *'''DDR1 and DDR2 tyrosine kinase receptors''' see [[Epithelial discoidin domain-containing receptor]] | ||
*'''c-Met tyrosine kinase''' see [[Hepatocyte growth factor receptor]] | *'''c-Met tyrosine kinase''' see [[Hepatocyte growth factor receptor]] | ||
Revision as of 07:32, 14 June 2022
3D structures of tyrosine kinase
Updated on 14-June-2022 - For a general description of the protein see Tyrosine kinase {{#tree:id=OrganizedByTopic|openlevels=0|
- NON-RECEPTOR TYROSINE KINASES - nRTK
- Fyn tyrosine kinase (Domains: SH3 80-141; SH2 142-247; kinase 260-537)
- 1shf, 3ua6, 7a2j, 7a2k – hTK Fyn SH3 domain – human
- 3h0f, 3h0h, 3h0i, 3cqt, 6ipz, 6ipy, 7a2l, 7a2m, 7a2n, 7a2o, 7a2p, 7a2q, 7a2r,7a2s, 7a2t, 7a2u, 7a2v - hTK Fyn SH3 domain (mutant)
- 1zbj - hTK Fyn SH3 domain – NMR
- 1g83 - hTK Fyn SH2+SH3 domains (mutant)
- 6edf - hTK Fyn residues 1-77
- 3uf4 – mTK Fyn SH3-SH2 domain – mouse
- 3uf4 - mTK Fyn SH2+SH3 domains
- 2l2p, 2lp5 - cTK Fyn SH3 domain (mutant)- chicken - NMR
- 1shf, 3ua6, 7a2j, 7a2k – hTK Fyn SH3 domain – human
- Fyn complex
- 1fyn, 4znx - hTK Fyn SH3 domain + peptide
- 1nyf, 1nyg, 1a0n, 1azg - hTK Fyn SH3 domain + peptide – NMR
- 1efn, 1avz - hTK Fyn SH3 domain + HIV Nef protein
- 4d8d, 7d7s - hTK Fyn SH3 domain (mutant) + HIV Nef protein
- 1m27 - hTK Fyn SH3 domain + SH2 domain protein 1A + SLAM peptide
- 4d8d - hTK Fyn SH3 domain (mutant) + HIV Nef protein
- 3ua7 – hTK Fyn SH3 domain + hepatitis virus peptide
- 4eik - hTK Fyn SH3 domain + VSL12 peptide
- 7a2w, 7a2x, 7a2y, 7a2z - hTK Fyn SH3 domain (mutant) + VSL12 peptide
- 1aot, 1aou - hTK Fyn SH2 domain + phosphopeptide - NMR
- 2dq7 – hTK kinase domain + staurosporine
- 1fyn, 4znx - hTK Fyn SH3 domain + peptide
- Abelson tyrosine kinase
- Abl1 SH2 domain residues 120-220
- Abl1 SH3 domain residues 60-121
- 5oaz - hTK SH3 domain
- 1ju5 - hTK SH3 domain (mutant) + CRK SH2 domain + phosphopeptide - NMR
- 1awo - hTK SH3 domain + phosphopeptide – NMR
- 1bbz - hTK SH3 domain + peptide
- 2o88 - hTK SH3 domain (mutant} + peptide
- 4jjb, 4jjc, 4jjd - hTK abl SH3 domain
- 4j9b, 3egu, 3eg2, 3eg3, 3eg0, 3eg1 - hTK abl SH3 domain (mutant)
- 4j9c, 4j9e, 4j9i - hTK abl SH3 domain (mutant) + p17 peptide
- 4j9d, 4j9f - hTK abl SH3 domain (mutant) + p0 peptide
- 4j9g, 4j9h - hTK abl SH3 domain (mutant) + p7 peptide
- 1abo - mTK SH3 domain + peptide
- 1abq - mTK SH3 domain
- 5oaz - hTK SH3 domain
- Abl1 SH3-SH2 domain residues 57-218
- Abl1 regultory module residues 1-255
- Abl1 kinase domain residues 229-512
- 6bl8 - hTK kinase domain
- 2g2h - hTK kinase domain (mutant)
- 6xr6, 6xr7, 6xrg - hTK kinase domain (mutant) - NMR
- 2g1t - hTK kinase domain + peptide
- 2g2i, 2g2f - hTK kinase domain (mutant) + peptide
- 3ue4, 3cs9, 2hzi, 2hz4, 2hz0, 2hyy, 2gqg, 4wa9, 7n9g - hTK kinase domain + cancer drug
- 2f4j, 4twp - hTK kinase domain (mutant) + cancer drug
- 3qrk, 3qri, 3qrj, 2v7a, 2e2b, 2hiw, 4zog, 5hu9, 4yc8, 3pyy, 6npv, 6npu, 6npe, 7cc2, 7dt2, 7w7x, 7w7y - hTK kinase domain + inhibitor
- 1opj, 1opk - mTK kinase domain
- 1fpu, 1m52, 2qoh, 3kf4, 3kfa - mTK kinase domain + inhibitor
- 2z60, 3dk3, 3dk6, 3dk7 - mTK kinase domain (mutant) + inhibitor
- 1iep, 2hzn, 3k5v, 3ms9, 3mss, 3oxz - mTK kinase domain + cancer drug
- 3ik3, 3oy3 - mTK kinase domain (mutant) + cancer drug
- 6hd4, 6hd6 - mTK kinase domain + cancer drug + inhibitor
- 6bl8 - hTK kinase domain
- Abl1 SH2-kinase domain residues 119-531
- 4xey - hTK SH2-kinase domain
- 4xey - hTK SH2-kinase domain
- Abl1 SH3-SH2-kinase domain residues 1-531
- 1opl - hTK SH3-SH2-kinase domain (mutant}
- 1opl - hTK SH3-SH2-kinase domain (mutant}
- Abl1 F-actin binding domain residues 1007-1130
- 1zzp - hTK abl F-actin binding domain – NMR
- 1zzp - hTK abl F-actin binding domain – NMR
- Abl2 SH2 domain residues 165-273
- Abl2 kinase domain residues 279-546
- Abl2 C-terminal residues 1058-1182
- 2kk1 – hTK C terminal – NMR
- 2kk1 – hTK C terminal – NMR
- Anaplastic lymphoma kinase (Alk) or Alk tyrosine kinae receptor; Domains – Gly-rich 678-986; TG+EGF=like 648-1030; kinase 1093-1411
- 4tt7, 6cdt - hTK kinase domain
- 3l9p, 3lcs, 3lct, 2yhv, 2yjr, 2yjs, 4fnw, 4fnx, 4anl - hTK kinase domain (mutant)
- 7lrz, 7mzw, 7mzy - hTK Gly-rich domain
- 7nx4 - hTK TG+EGF-like domain
- 7nx3 - hTK TG+EGF-like domain + antibody
- 2xb7, 2xba, 3aox, 5imx, 5kz0, 4ccb, 4ccu, 4cli, 4cmo, 4cmt, 4cmu, 4cnh, 4ctb, 4ctc, 6mx8, 6edl, 6ebw, 6e0r, 7btt, 7jy4, 7jyr, 7jys, 7jyt - hTK kinase domain + inhibitor
- 4dce, 4fob, 4foc, 4fod, 4fny, 4fnz, 4joa, 4mkc, 4z55, 5iug, 5iuh, 5iui, 4cd0, 4clj - hTK kinase domain (mutant) + inhibitor
- 2xp2, 5j7h, 5fto, 5ftq - hTK kinase domain + cancer drug
- 2yfx, 4anq, 4ans, 5aaa, 5aab, 5aac, 5a9u, 5aa8, 5aa9 - hTK kinase domain (mutant) + cancer drug
- [[7n00], 7nwz] - hTK kinase domain (mutant) + AUG-alpha
- 7ls0 - hTK kinase domain/AUG-alpha
- 4tt7, 6cdt - hTK kinase domain
- Csk tyrosine kinase
- Jak tyrosine kinase see Janus kinase
- p55-blk tyrosine kinase
- Src tyrosine kinase or proto-oncogene tyrosine protein kinase (Domains: SH3 85-140; SH2 140-251; kinase 253-535)
- Src tyrosine kinase SH2 domain
- 3eac - hTK
- 4f59, 3eaz - hTK (mutant)
- 4f5b - hTK (mutant) + phosphotyrosine
- 4f5a - hTK (mutant) + phosphate
- 1o4c - hTK + phosphate
- 1o41, 1o42, 1o43, 1o44, 1o45, 1o46, 1o47, 1o48, 1o49, 1o4a, 1o4b, 1o4d, 1o4e, 1o4f, 1o4g, 1o4h, 1o4i, 1o4j, 1o4k, 1o4l, 1o4m, 1o4n, 1o4o, 1o4p, 1o4q, 1o4r - hTK + inhibitor
- 1hcs, 1hct - hTK + peptide - NMR
- 1a07, 1a08, 1a09, 1a1a, 1a1b, 1a1c, 1a1e - hTK + peptide
- 1f2f - cTK (mutant)
- 1shd - cTK + TRKA receptor
- 1p13 - cTK + peptide
- 1f1w - cTK (mutant) + peptide
- 1spr - RsvTK + phosphate – Rous sarcoma virus
- 2jyq – RsvTK – NMR
- 1kc2, 1sps, 1is0, 1nzl, 1nzv - RsvTK + peptide
- 1sha, 1shb - RsvTK + phosphopeptide
- 1qwe, 1qwf - RsvTK + peptide
- 3eac - hTK
- Src tyrosine kinase SH3 domain
- 6c4s – hTK + choline kinase peptide
- 1jeg – mTK + protein-tyrosine phosphatase peptide
- 1srl, 1srm - cTK – NMR
- 3fj5, 4jz3, 4jz4, 6xvo, 6xvn - cTK
- 4le9, 4oml, 4omm, 4omn, 4omo, 4omp, 4omq, 5i11, 4rtu, 4rtx, 7a30, 7a31, 7a32, 7a33, 7a34, 7a35, 7a36, 7a37, 7a38, 7a39, 7a3a, 7a3b, 7a3c, 7a3d, 7a3e, 7ner, 7nes, 7net - cTK (mutant)
- 6xx3, 6xx2, 6xx5, 6xx4, 6xx5, 6xx2 - cTK (mutant) + ion
- 4hxj, 1prl, 4qt7, 4rty, 4rtz - cTK + peptide
- 1prm, 1rlp, 1rlq, 1nlo, 1nlp - cTK + peptide - NMR
- 4hvu, 4hvv, 4hvw, 4rtv, 4rtw, 5ob2, 5ob1, 5ob0, 5oav - cTK (mutant) + peptide
- 4y92 - TK (mutant) - Avian sarcoma virus
- 6c4s – hTK + choline kinase peptide
- Src tyrosine kinase kinase domain residues 253-535
- 1yo6 - hTK
- 1yoj - hTK (mutant)
- 2bdf, 2bdj, 6e6e, 6ate, 7ng7 – hTK + inhibitor
- 1yol, 1yom – hTK (mutant) + inhibitor
- 1byg – hTK + staurosporine
- 4mxo – hTK + cancer drug
- 4mxx, 4mxy, 4mxz – hTK (mutant) + cancer drug
- 3of0, 2qi8 - cTK (mutant)
- 3d7t, 3d7u – cTK + Csk
- 3dqw, 3dqx - cTK (mutant) + ATP
- 3tz7, 3tz8, 3tz9, 4dgg – cTK (mutant) + pyrazolin derivative
- 4fic, 3uqg, 3uqf, 3u51, 3u4w, 4agw, 3qlg, 3qlf, 3g6g, 3el8, 3f6x, 2hwo, 2hwp, 2oiq, 3en4, 3en5, 3en6, 3en7, 3el7, 5bmm, 5j5s, 4ybj, 4ybk, 5xp7, 7ah3, 7d57, 7d5o – cTK + inhibitor
- 7wf5 – cTK + cancer drug
- 4lgg, 4lgh, 3svv, 3oez, 3lok, 3g5d, 3f3w, 3f3v, 3geq, 3g6h, 3f3t, 3f3u, 2qlq, 2qq7, 4lgg, 4lgh, 4mcv, 4o2p, 5teh, 5t0p, 5sys, 5swh, 6hve, 6hvf – cTK (mutant) + inhibitor
- 4u5j – cTK (mutant) + cancer drug
- 1yo6 - hTK
- Src tyrosine kinase C terminal domain
- 1k9a – rTK
- 1k9a – rTK
- Src tyrosine kinase SH2+SH3+kinase domains residues 85-535
- Src tyrosine kinase SH2+SH3+kinase+C terminal domains
- Src tyrosine kinase N terminal+SH2+SH3+kinase domains
- 2h8h – hTK + inhibitor
- 2h8h – hTK + inhibitor
- Lymphocyte-specific tyrosine kinase Lck (Domains: SH3 58-118; SH2 122-225; kinase 230-500)
- Lck complex
- 1lcj, 1lkk, 1lkl - hTK Lck SH2 domain (mutant) + phosphopeptide
- 1cwd, 1cwe, 1ijr - hTK Lck SH2 domain + phosphopeptide
- 1bhf - hTK Lck SH2 domain + peptide inhibitor
- 1fbz - hTK Lck SH2 domain + inhibitor
- 1bhh - hTK Lck SH2 domain + T-lymphocyte-specific TK
- 5mtm, 5mtn - hTK Lck SH2 domain + monobody
- 1lck - hTK Lck SH3-SH2 domain (mutant) + phosphopeptide
- 1x27 - hTK Lck SH3-SH2 domain + peptide
- 1qpj - hTK Lck kinase domain + staurosporin
- 2of2, 2of4, 2ofu, 2ofv, 2og8, 3b2w, 3bym, 3bys, 3byu, 2zm1, 2zm4, 3byo, 2zyb, 3ac1, 3ac2, 3ac3, 3ac4, 3ac5, 3ac8, 3acj, 3ack, 3kmm, 3ad4, 3ad5, 3ad6, 1qpc, 1qpd, 1qpe, 6pdj - hTK Lck kinase domain + inhibitor
- 3mpm - hTK Lck kinase domain (mutant) + inhibitor
- 4c3f - hTK Lck kinase domain (mutant) + chemotype
- 2pl0 - hTK Lck kinase domain + anti-cancer drug
- 3kxz - hTK Lck kinase domain + probe molecule
- 1q68 - hTK Lck residues 6-34 (mutant) + CD4 peptide – NMR
- 1q69 - hTK Lck residues 6-34 (mutant) + CD8 – NMR
- 1lcj, 1lkk, 1lkl - hTK Lck SH2 domain (mutant) + phosphopeptide
- Syk - spleen tyrosine kinase
- Syk complex
- 1xbb - hSyk kinase domain + Gleevec
- 1xbc - hSyk kinase domain + staurosporine
- 3emg, 3fqe, 3fqh, 3fqs, 3srv, 4dfl, 4dfn, 3vf8, 3vf9, 3tub, 3tuc, 3tud, 4f4p, 4fyn, 4fyo, 4fz6, 4fz7, 4gfg, 4i0r, 4i0s, 4i0t, 4puz, 4pv0, 4rx7, 4rx8, 4rx9, 5lma, 5lmb, 5ghv, 4wnm, 4xg3, 4xg4, 4xg6, 4xg7, 4xg8, 4xg9, 4rss, 4yjv, 5c26, 5c27, 4yjo, 4yjp, 4yjq, 4yjr, 4yjs, 4yjt, 4yju, 5tr6, 5tt7, 5tiu, 5t68, 5y5t, 5y5u, 4gfg, 6hm6, 6hm7, 6vov, 6zc0, 6zcp, 6zcq, 6zcr, 6zcs, 6zcu, 6zcx, 6zcy - hSyk kinase domain + inhibitor
- 4px6, 5cxh, 5cxz, 5cy3 - hSyk kinase domain (mutant) + inhibitor
- 1csy, 1csz - hSyk SH2 domain + phosphopeptide – NMR
- 4fl1, 4fl2 - hSyk kinase domain + ANP
- 4fl3 - hSyk kinase domain (mutant) + ANP
- 7q63, 7sa7 – hSyk tandem SH2 domain
- 1a81, 7q5t, 7q5u, 7q5w – hSyk tandem SH2 domain + T-cell surface peptide
- 1xbb - hSyk kinase domain + Gleevec
- Itk/Tsk tyrosine kinase or interleukin-2 tyrosine kinase; domains – SH2 236-344; SH3 160-236; kinase 357-620
- 2etz, 2eu0 – hTK Itk SH2 domain + phosphopeptide – NMR
- 2yuq, 2lmj – hTK Itk SH3 domain – NMR
- 1sm2, 1snu, 1snx – hTK Itk kinase domain
- 3miy – hTK Itk kinase domain + cancer drug
- 3v5j, 3v5l, 3v8t, 3v8w – hTK Itk kinase domain + inhibitor
- 3mj1, 3mj2, 3qgw, 3qgy, 4hct, 4hcu, 4hcv, 4kio – hTK Itk kinase domain (mutant) + inhibitor
- 3t9t – hTK Itk kinase domain (mutant) + arthritis drug
- 2e6i – hTK Itk BTK motif – NMR
- 4l7s, 4m0y, 4m0z, 4m12, 4m13, 4m14, 4m15, 4mf0, 4mf1, 3v5j, 3v5l, 3v8t, 3v8w - hTK Itk kinase domain + inhibitor
- 4pp9, 4ppa, 4ppb, 4ppc, 4pqn, 4qd6, 4rfm, 4kio - hTK Itk kinase domain (mutant) + inhibitor
- 1lui, 1luk, 1lum, 1lun – mTK Itk SH2 domain – NMR
- 3s9k – mTK Itk SH2 domain
- 1awj, 2rn8, 2rna – mTK Itk SH3 domain – NMR
- 2k79, 2k7a – mTK Itk SH2+SH3 domains – NMR
- 2etz, 2eu0 – hTK Itk SH2 domain + phosphopeptide – NMR
- Zap-70 tyrosine kinase (Domains: SH2 1-259; kinase 327-606
- Zap-70 complex
- Pyk2 tyrosine kinase or or protein-tyrosine kinase 2-β (Domains: kinase 414-692; FAT 861-1009)
- Pyk2 complex
- 3fzp - hTK Pyk2 kinase domain + ATPγS
- 3fzr, 3fzs, 3fzt, 3h3c, 3et7, 5to8, 5tob, 4h1j, 4h1m - hTK Pyk2 kinase domain + inhibitor
- 3gm1, 4r32 - hTK Pyk2 FAT domain + paxillin peptide
- 4xek, 4xev, 4xef - hTK Pyk2 FAT domain + leupaxin peptide
- 4h1j - hFAK2 kinase domain + pyrazole inhibitor
- 3h3c - hFAK2 kinase domain + pyrimidine inhibitor
- 4h1m - hFAK2 kinase domain + indole inhibitor
- 3u3f – hFAK2 FAT domain (mutant) + paxillin LD2 motif
- 3fzp - hTK Pyk2 kinase domain + ATPγS
- CapAB tyrosine kinase
- Fer tyrosine kinase
- Ptk6 tyrosine kinase or breast tumor kinase Brk
- PtkA tyrosine kinase
- 6f2x - TK PtkA – Mycobacterium tuberculosis - NMR
- 6f2x - TK PtkA – Mycobacterium tuberculosis - NMR
- Lyn tyrosine kinase (Domains: SH3 39-101; SH2 115-229; kinase 239-512)
- 4tzi - hTK Lyn SH2 domain
- 6nmw - hTK Lyn SH3 domain
- 1w1f - hTK Lyn SH3 domain – NMR
- 1wa7 - hTK Lyn SH3 domain + peptide – NMR
- 3a4o - hTK Lyn residues 233-512 + staurosporine
- 5xy1 - hTK Lyn kinase domain + inhibitor
- 2zv7 - mTK Lyn kinase domain
- 2zv8 - mTK Lyn kinase domain + AMPPNP
- 2zv9 - mTK Lyn kinase domain + PP2
- 2zva - mTK Lyn kinase domain + cancer drug
- 4tzi - hTK Lyn SH2 domain
- Txk tyrosine kinase
- 2dm0 - hTK Txk SH2 domain – NMR
- 2dm0 - hTK Txk SH2 domain – NMR
- Yes tyrosine kinase
- Tec tyrosine kinase
- Fes/Fps tyrosine kinase
- Etk tyrosine kinase
- 3cio - EcTK Etk kinase domain – Escherichia coli
- 3cio - EcTK Etk kinase domain – Escherichia coli
- Wzc tyrosine kinase
- Ros tyrosine kinase
- Non-receptor Tyk2 tyrosine kinase (Domains: SH2+FERM 23-540; pseudokinase 541-880; kinase 880-1170)
- 5f20, 5f1z, 6ova - hTK Tyk2 kinase domain + inhibitor
- 3lxn, 3lxp, 3nyx, 3nz0, 4e1z, 4e20, 4gfo, 4gih, 4gii, 4gj2, 4gj3, 4py1, 5wal, 5wev, 6dbk, 6dbm - hTK Tyk2 kinase domain (mutant) + inhibitor
- 6aam, 6x8g, 6x8f - hTK Tyk2 kinase domain (mutant) + drug
- 4gvj - hTK Tyk2 kinase domain (mutant) + ADP
- 4oli - hTK Tyk2 pseudokinase + kinase domains
- 3zon, 5c01, 5c03 - hTK Tyk2 pseudokinase domain
- 4wov, 5tkd, 6nzr, 6nzq, 6nzp, 6nzh, 6nzf, 6nze, 6nsl, 7ax4, 7k7o, 7k7q - hTK Tyk2 pseudokinase domain + inhibitor
- 4po6 - hTK Tyk2 SH2+FERM domains + IFNAR1 peptide
- 5f20, 5f1z, 6ova - hTK Tyk2 kinase domain + inhibitor
- Hck tyrosine kinase Domains: SH3 81-137; SH2 119-224; SH1 or kinase+C-terminal 225-525;
- 3hck - hTK SH2 domain - NMR
- 1bu1 - hTK SH3 domain
- 4hck, 5hck - hTK SH3 domain - NMR
- 2oj2, 2oi3 - hTK SH3 domain + peptide - NMR
- 3rbb, 3rea, 3reb - hTK SH3 domain (mutant) + HIV NEF
- 5nuh - hTK SH3 domain + SIV NEF
- 4orz - hTK SH3 domain (mutant) + HIV NEF + single domain antibody
- 3nhn - hTK SH3-SH2-linker domain
- 4u5w - hTK Hck SH3-SH2 domains + NEF
- 2c0i, 2c0o, 2c0t - hTK SH3-SH2-SH1 domain + inhibitor
- 5h0b, 5h0e, 5h0g, 5h0h - hTK SH3-SH2-SH1 domain (mutant) + inhibitor
- 2hk5, 5zj6 - hTK kinase domain + inhibitor
- 1qcf, 3vrz, 3vs0, 3vs3, 3vs4, 3vs5, 3vs6, 3vs7 - hTK SH3-SH2-kinase-C-terminal domain + inhibitor
- 3vry, 3vs1, 3vs2 - hTK SH3-SH2-kinase-C-terminal domain (mutant) + inhibitor
- 1ad5 - hTK SH3-SH2-kinase-C-terminal domain + AMPPNP
- 2hck - hTK SH3-SH2-kinase-C-terminal domain + quercetin
- 4lud, 4lue - hTK SH2+SH3+kinase+C-terrminal domain (mutant) + fluorescent compound
- 3hck - hTK SH2 domain - NMR
- Ack1 tyrosine kinase or activated cdc42 kinase 1
- RECEPTOR TYROSINE KINASES - RTK
- Bruton’s tyrosine kinase (Domains: PH 1-170; SH3 216-273; SH2 273-378; kinase 378-659)
- Btk complex
- 1b55 - hTK Btk PH domain + inositol-tetrakisphosphate
- 1bwn - hTK Btk PH domain (mutant) + inositol-tetrakisphosphate
- 6yyf, 6yyg, 6yyk - hTK Btk PH domain (mutant) + inhibitor
- 3gen, 3ocs, 3pix, 3piy, 3piz, 3pj1, 3pj2, 3pj3, 4nwm, 4yhf, 5jrs, 5fbo, 5fbn, 4rx5, 5bpy, 5bq0, 5vgo, 5u9d, 5t18, 5p9m, 5p9l, 5p9m, 5p9l, 5p9f, 5p9g, 5p9h, 5p9i, 5p9j, 5p9k, 5vfi, 4z3v, 4zly, 4zlz, 5zz4, 6aua, 6aub, 5j87, 5xyz, 6bik, 6bke, 6bkh, 6bkw, 6bln, 6di0, 6di1, 6di3, 6di5, 6di9, 6e4f, 6e9p, 5kup, 6tfp, 6s90, 6o8i, 6nzm, 6nfi, 6nfh, 6n9p, 6w07, 6w06, 6vxq, 6x3n, 6x3o, 6x3p, 6xe4, 7kxl, 7kxm, 7kxn, 7kxo, 7kxp, 7kxq, 7lty, 7ltz, 7n4q, 7n4r, 7n4s, 7n5o, 7n5r, 7n5x, 7n5y, 7r60, 7r61 - hTK Btk kinase domain + inhibitor
- 3k54, 3t9t, 4ot5, 4ot6, 4otq, 4otr, 4otf, 4rfy, 4rfz, 4rg0, 6ep9, 6hrt, 6hrp - hTK Btk kinase domain (mutant) + inhibitor
- 6w7o, 6w8i - hTK Btk kinase domain + cIAP + inhibitor
- 5vgo - hTK Btk kinase domain + cancer drug
- 3oct - hTK Btk kinase domain (mutant) + cancer drug
- 6omu - hTK Btk kinase domain + MS drug
- 6j6m - hTK Btk kinase domain + MCL drug
- 4y94 - bTK Btk kinase domain + inhibitor
- 6mny - mTK Btk kinase domain + inhibitor
- 1b55 - hTK Btk PH domain + inositol-tetrakisphosphate
- c-FMS tyrosine kinase or macrophage colony-stimulating factor 1 receptor see Colony-stimulating factor receptor
- Kit tyrosine kinase or mast/stem cell growth factor receptor Kit; Domains – extracellular 1-519; kinase 547-693, 754-935
- 2ec8 - hTK Kit extracellular domain
- 3g0e, 3g0f - hTK Kit kinase domain (mutant) + cancer drug
- 2e9w - hTK Kit extracellular domain + stem cell factor
- 1t45, 4pgz - hTK Kit kinase domain
- 1t46, 4u0i, 6mob, 6kla - hTK Kit kinase domain + cancer drug
- 6gqj, 6gql, 6gqm, 6gqk - hTK Kit kinase domain (mutant) + cancer drug
- 6itv, 6itt, 6xv9, 6xva, 6xvb, 7khg, 7khj, 7khk - hTK Kit kinase domain + inhibitor
- 4hvs, 6hh1 - hTK Kit kinase domain (mutant) + inhibitor
- 2o26 - hTK Kit residues 25-314 + Kit ligand
- 4k94, 4k9e - hTK Kit residues 308-518 + antibody
- 2ec8 - hTK Kit extracellular domain
- Mer tyrosine kinase (Domains: FN3 373-483; kinase 570-864)
- Mer complex
- 7ab0 - hTK Mer kinase domain
- 3brb - hTK Mer kinase domain + ADP
- 2p0c - hTK Mer kinase domain + ANP
- 3bpr, 3tcp, 4m3q, 4mh7, 4mha, 5u6c, 5tc0, 5k0k, 5k0x, 5td2, 6mep, 7m5z - hTK Mer kinase domain + inhibitor
- 7ab2, 7aax, 7aaz - hTK Mer kinase domain (mutant) + inhibitor
- 7ab1 - hTK Mer kinase domain + anti-cancer drug
- 7aay - hTK Mer kinase domain (mutant) + anti-cancer drug
- 7ab0 - hTK Mer kinase domain
- Bone marrow tyrosine kinase; Domains – kinase 411-675
- Bone marrow tyrosine kinase complex
- ErbB tyrosine kinase see Epidermal Growth Factor Receptor
- MuSK tyrosine kinase
- Sgk223 tyrosine kinase or sugen kinase
- 5ve6 - hTK
- 5ve6 - hTK
- Matk tyrosine kinase or megakaryocyte-associated tyrosine-protein kinase
- Flt3 tyrosine kinase
- Tie2 tyrosine kinase
- 1fvr - hTK Tie2 kinase domain
- 1fvr - hTK Tie2 kinase domain
- Ret tyrosine kinase or proto-oncogene tyrosine protein kinase receptor Ret
- hTK Ret kinase domain + cancer drug
- 4ux8 - hTK Ret extracellular domain + GFR alpha 1
- 4ux8 - hTK Ret extracellular domain + GFR alpha 1
- DDR1 and DDR2 tyrosine kinase receptors see Epithelial discoidin domain-containing receptor
- c-Met tyrosine kinase see Hepatocyte growth factor receptor
}}